Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. See ...

BridgeBio has received a $300 million upfront payment, strengthening the Company’s balance sheet, and supporting the launch ...

Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly boost your returns by picking above-average stocks. For example, the Royalty ...

Royalty Pharma’s first quarter reflected a stable performance, with revenue in line with Wall Street expectations and ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

This transaction provides a non-dilutive capital infusion of $7 million to Ovid, which will support the Company’s ongoing operations. In 2024, Ovid recorded approximately $566,000 in ganaxolone ...

The funding will support the development of Revolution's RAS(ON) inhibitor daraxonrasib in exchange for tiered royalties on its sales.

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Royalty Pharma will pay up to $2 billion to Revolution Medicines to support the development and sales of an experimental drug ...

Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new ...

A total of $1.25 billion of the money pledged by Royalty has been agreed in exchange for tiered royalties on net sales of ...

According to Benzinga Pro, Royalty Pharma's peer group average for short interest as a percentage of float is 3.78%, which means the company has more short interest than most of its peers. Did you ...